Figure 4.
Experiment 2: The effect of CB receptor agonist (WIN55–212,2 0.1, 0.5 and 1 mg kg−1; i.p.) treatment upon harmaline (30 mg kg−1; i.p.) induced symptoms. (A) Time spent on rotarod apparatus and (B) gripping time in the wire grip test. Results from the same treatment in the gait analysis test are shown as (C) hind paw stride width (cm), (D) right hind paw stride length (cm) and (F) left hind paw stride length (cm). Data for all measures in this experiment were not normally distributed and are represented as medians with interquartile ranges as a box and maxima/minima as whiskers. * P < 0.05, significantly different from the harmaline only group. Numbers in parentheses indicate group sizes. 3/199 data points were detected as outliers and excluded from the presented analyses.